Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Ligand Pharmaceuticals

Ligand Pharmaceuticals Shows Rising Price Performance With Jump To 84 RS Rating

Ligand Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 84.

Investors Business Daily

Ligand Pharmaceuticals Stock Earns 84 RS Rating

Ligand Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 84.

Investors Business Daily

Ligand Pharmaceuticals Shows Rising Price Performance With Jump To 82 RS Rating

A Relative Strength Rating upgrade for Ligand Pharmaceuticals shows improving technical performance.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

IBD Rating Upgrades: Ligand Pharmaceuticals Shows Improved Relative Price Strength

A Relative Strength Rating upgrade for Ligand Pharmaceuticals shows improving technical performance. Will it continue?

Investors Business Daily

Ligand Pharmaceuticals Earns Relative Strength Rating Upgrade; Hits Key Benchmark

Ligand Pharmaceuticals sees its Relative Strength Rating hit the 80-plus level.

Investors Business Daily

3 'Strong Buy' Small-Cap Stocks to Snag Now for a Soft Landing

Explore three small-cap stocks with 'Strong Buy' ratings that are poised for significant growth as economic conditions hint at a potential soft landing.

Barchart

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ:BMRN) lead asset ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients. BioMarin shares traded as high as 2.28 percent, in a range of $91.39 to $93.68…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Barclays Maintains Overweight Rating for Ligand Pharmaceuticals: Here's What You Need To Know

Barclays has decided to maintain its Overweight rating of Ligand Pharmaceuticals (NASDAQ:LGND) and lower its price target from $165.00 to $157.00. Shares of Ligand Pharmaceuticals are trading up 1.79% over the last 24 hours, at $92.20 per share.

Benzinga

Recap: Ligand Pharmaceuticals Q4 Earnings

Ligand Pharmaceuticals (NASDAQ:LGND) reported its Q4 earnings results on Thursday, February 17, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Organisations

Investor Business Daily

1,211 stories

US Food and Drug Administration

57 stories

Apellis Pharmaceuticals

Biomarin Pharmaceutical

15 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.